Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 7, 2024
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24
New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases’ (AASLD’s) The Liver Meeting 2024
Read more at globenewswire.com
